Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Want to see LTRN full AI Analyst Report?
Top Page
Lantern Pharma
(NASDAQ:LTRN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.00
▲(32.45% Upside)
Action:Reiterated
Date:06/03/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and heavy cash burn). Technicals are constructive with strong trend signals, but overbought indicators temper that strength. Corporate events are moderately supportive (pipeline progress and added capital), while valuation remains constrained by negative earnings and no dividend.
Positive Factors
AI platform spinoff (withZeta.ai / RADR)
Creating an independent AI subsidiary around withZeta.ai and RADR institutionalizes a proprietary platform as a standalone product/service. This can create recurring licensing/subscription revenue streams, attract dedicated partners, and clarify capital allocation and strategic focus over the medium term.
Negative Factors
No product revenue
Absence of commercial revenue means operations rely entirely on financing or partnerships rather than internal cash generation. This structural profile raises execution risk: future development, commercialization or platform monetization must succeed to achieve sustained, self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
AI platform spinoff (withZeta.ai / RADR)
Creating an independent AI subsidiary around withZeta.ai and RADR institutionalizes a proprietary platform as a standalone product/service. This can create recurring licensing/subscription revenue streams, attract dedicated partners, and clarify capital allocation and strategic focus over the medium term.
Read all positive factors
Lantern Pharma (LTRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.36M
Dividend YieldN/A
Average Volume (3M)293.55K
Price to Earnings (P/E)―
Beta (1Y)2.31
Revenue GrowthN/A
EPS Growth21.67%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.45
Shares Outstanding12,758,872
10 Day Avg. Volume223,536
30 Day Avg. Volume293,553
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.62K
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
Lantern Pharma Business Overview & Revenue Model
Company Description
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug ca...
How the Company Makes Money
Lantern Pharma is a clinical-stage biotechnology company; as such, it generally does not generate significant recurring revenue from product sales because its drug candidates are still in development and not broadly commercialized. Specific, up-to...
Lantern Pharma Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.Positive Updates
Successful LP-184 Phase Ia Clinical Trial
The LP-184 Phase Ia clinical trial successfully achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients who received doses at or above the therapeutic threshold.
Negative Updates
Decrease in R&D Expenses
R&D expenses decreased to $2.4 million from $3.7 million year-over-year, primarily due to reductions in research study and materials expenses, consulting, and payroll.
Read all updates
Q3-2025 Updates
Positive
Negative
Successful LP-184 Phase Ia Clinical Trial
The LP-184 Phase Ia clinical trial successfully achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients who received doses at or above the therapeutic threshold.
Read all positive updates
Company Guidance
During Lantern Pharma's third quarter 2025 earnings call, the company highlighted several key metrics and milestones, signaling a transformative period. The LP-184 Phase Ia clinical trial achieved all primary endpoints with a 48% clinical benefit rate in cancer patients, particularly those with DNA damage repair mutations. The company also advanced its AI platform, RADR, and outlined future plans for its CNS-focused subsidiary, Starlight Therapeutics. Financially, Lantern reported a net loss of $4.2 million, or $0.39 per share, for the quarter, with $12.4 million in cash and equivalents, providing runway until the third quarter of 2026. The company also discussed its strategic approach to drug development, leveraging AI to identify high-probability success areas, and detailed upcoming clinical trials targeting a combined market opportunity exceeding $7 billion.Lantern Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.85K | 0.00 | 0.00 | -174.84K | 0.00 | 0.00 |
| EBITDA | -15.90M | -17.10M | -20.76M | -15.79M | -14.05M | -12.36M |
| Net Income | -15.91M | -17.12M | -20.78M | -15.96M | -14.26M | -12.36M |
Balance Sheet | ||||||
| Total Assets | 7.22M | 11.04M | 25.57M | 43.65M | 58.84M | 73.95M |
| Cash, Cash Equivalents and Short-Term Investments | 6.32M | 10.12M | 24.01M | 41.30M | 55.20M | 70.73M |
| Total Debt | 59.08K | 78.54M | 243.66K | 234.47K | 52.89K | 204.95K |
| Total Liabilities | 3.78M | 4.50M | 4.38M | 2.74M | 2.80M | 2.38M |
| Stockholders Equity | 3.45M | 6.53M | 21.19M | 40.91M | 56.04M | 71.57M |
Cash Flow | ||||||
| Free Cash Flow | -15.07M | -15.68M | -17.83M | -14.37M | -12.80M | -10.61M |
| Operating Cash Flow | -15.07M | -15.68M | -17.81M | -14.35M | -12.77M | -10.59M |
| Investing Cash Flow | 12.07M | 11.06M | 3.37M | -930.21K | 179.27K | -19.53M |
| Financing Cash Flow | 1.50M | 1.50M | 66.71K | -500.00K | -2.18M | 63.42M |
Lantern Pharma Technical Analysis
Positive
3.02
Price Trends
2.92
Positive
2.70
Positive
3.23
Positive
Market Momentum
0.28
Positive
58.58
Neutral
54.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Positive. The current price of 3.02 is below the 20-day moving average (MA) of 3.68, above the 50-day MA of 2.92, and below the 200-day MA of 3.23, indicating a bullish trend. The MACD of 0.28 indicates Positive momentum. The RSI at 58.58 is Neutral, neither overbought nor oversold. The STOCH value of 54.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LTRN.
Lantern Pharma Risk Analysis
Lantern Pharma disclosed 72 risk factors in its most recent earnings report. Lantern Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations. Q4, 2023
Lantern Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $48.36M | -2.68 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $41.45M | -2.85 | -138.61% | ― | 520.42% | 16.12% | |
42 Neutral | $25.92M | -0.37 | -4086.31% | ― | ― | -73.57% | |
41 Neutral | $24.86M | -0.49 | -217.27% | ― | ― | -74.39% | |
40 Underperform | $6.07M | -0.11 | 166.67% | ― | -81.82% | 31.28% | |
| ― | $85.12M | -1.85 | -284.80% | ― | ― | 16.55% |
* Healthcare Sector Average
LTRN
Lantern Pharma
3.79
0.72
23.45%
SKYE
Skye Bioscience
0.71
-2.16
-75.37%
BCAB
BioAtla
3.66
-16.93
-82.24%
RNXT
RenovoRx
0.92
-0.49
-34.75%
MAIA
MAIA Biotechnology, Inc.
1.40
-0.33
-19.08%
MDCX
Medicus Pharma Ltd
0.46
-1.88
-80.47%
Lantern Pharma Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress
Positive
Jun 2, 2026
On June 1, 2026, Lantern Pharma Inc. used an investor-style presentation to support discussions of its Harmonic Phase 2 clinical trial evaluating LP-300. The materials were provided to stakeholders as part of a regulatory filing, underscoring the ...
Business Operations and StrategyPrivate Placements and Financing
Lantern Pharma raises capital, plans AI platform spinoff
Positive
May 14, 2026
On May 12, 2026, Lantern Pharma entered into a securities purchase agreement with institutional investors for a registered direct offering of common shares and pre-funded warrants, which closed on May 14, 2026 and generated approximately $4.4 mill...
Business Operations and StrategyProduct-Related Announcements
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers
Neutral
Apr 10, 2026
On April 9, 2026, Lantern Pharma Inc. conducted a live demonstration of its withZeta.ai platform, showcasing the multi-agentic AI co-scientist’s capabilities in rare cancer drug discovery, development and clinical trial design. The presentat...
Business Operations and StrategyFinancial Disclosures
Lantern Pharma Reports 2025 Results and Pipeline Progress
Positive
Mar 30, 2026
Lantern Pharma reported its fourth-quarter and full-year 2025 results on March 30, 2026, highlighting a year of clinical validation and strategic expansion across its AI-driven oncology pipeline, while reducing operating expenses by 19% year over ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.